Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment.

BACKGROUND AND OBJECTIVE

Binimetinib is approved for multiple indications at a therapeutic dose of 45 mg twice a day (BID), in combination with encorafenib. A clinical hepatic impairment (HI) study was designed to evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of binimetinib in participants with mild, moderate, and severe HI compared with demographically matched healthy participants with respect to age, gender, and body weight.

METHODS

Participants were enrolled according to National Cancer Institute (NCI) classification criteria for hepatic function based on their total bilirubin and aspartate aminotransferase levels at screening. Participants enrolled into Group 1 (normal hepatic function) were matched to participants enrolled into Groups 2, 3, and 4 (mild, moderate, and severe HI, respectively) with respect to age, gender, and body weight. Dose-normalized PK parameters were evaluated because of a difference in doses for the severe HI group compared to the other groups, with the dose reduction due to the increased exposures observed in the moderate HI group.

RESULTS

Among 27 PK evaluable participants, changes in binimetinib dose-normalized PK parameters C/D and AUC/D were minimal in participants with mild HI compared to the normal hepatic function group. Both the moderate and severe HI groups had significant changes as AUC/D increased by 81% and 111%, respectively, compared to the normal hepatic function group. Unbound AUC/D for the moderate and severe HI groups increased by 280% and 248% compared to the normal hepatic function group, respectively.

CONCLUSION

Based on these findings on total and unbound exposures, dose reductions are recommended for binimetinib in cancer patients with moderate and severe HI.

CLINICAL TRIAL REGISTRATION

ClinicalTrials.gov NCT02050815, registered 29 January 2014.